- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 249/12 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 249/12
Total number of patents in this class: 633
10-year publication summary
|
39
|
45
|
54
|
65
|
43
|
54
|
27
|
23
|
39
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 20387 |
22 |
| Theravance Biopharma R&D IP, LLC | 517 |
22 |
| Synta Pharmaceuticals Corp. | 191 |
21 |
| Bayer Pharma AG | 1085 |
17 |
| Bayer AG | 3206 |
14 |
| Ardea Biosciences, Inc. | 76 |
13 |
| UPL Limited | 551 |
11 |
| Yuhan Corporation | 226 |
11 |
| The Regents of the University of California | 19493 |
9 |
| FMC Corporation | 851 |
9 |
| King Faisal University | 825 |
9 |
| Inflazome Limited | 90 |
9 |
| F. Hoffmann-La Roche AG | 7939 |
8 |
| The General Hospital Corporation | 4642 |
8 |
| Bayer Cropscience AG | 2142 |
7 |
| Eli Lilly and Company | 3715 |
7 |
| Rigel Pharmaceuticals, Inc. | 585 |
7 |
| Bristol-myers Squibb Company | 4883 |
6 |
| President and Fellows of Harvard College | 5905 |
6 |
| Apotex Inc. | 205 |
6 |
| Other owners | 411 |